title: From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability.
abstract: BACKGROUND
  To evaluate the safety and tolerability of Polyquad-preserved Travoprost (PQ-Travoprost) in patients previously treated with benzalkonium chloride (BAK)-preserved Latanoprost.
  
  
  METHODS
  Cohort 6-month study on open-angle glaucoma or ocular hypertension patients. Complete ophthalmic examination, intraocular pressure (IOP) measurement and ocular surface status (tear film break-up time [TF-BUT], corneal staining and ocular surface disease index [OSDI]) were evaluated at baseline and 6 months later.
  
  
  RESULTS
  A total of 44 patients were enrolled. Median (interquartile range [IQR]) baseline IOP was 18 (15.5 - 21) and 16 (14 - 17) mmHg (p < 0.0001) after 6 months. At baseline, 18 (40.9%) patients presented an IOP of < 18 mmHg, 11 (25%) < 16 mmHg, 2 (4.3%) < 14 mmHg and 1 (2.3%) < 12 mmHg; 6 months later the proportions were 36 (81.8%) (p < 0.0001), 21 (47.7%) (p = 0.00075), 8 (18.2%) (p = 0.0143) and 6 (13.6%) (p = 0.0253). Concerning safety, TF-BUT improved from 8 [IQR 6 - 10] to 10 [IQR 8 - 12] s (p < 0.0001). No eye developed corneal staining; punctate keratitis was absent in 13 (29.5%) patients at baseline and in 31 (70.4%) after 6 months (p < 0.001). OSDI changed from 16 (10 - 30) to 9 (2 - 20).
  
  
  CONCLUSIONS
  No patient treated with PQ-Travoprost developed ocular surface disease after 6 months of monotherapy, whereas many patients reached a good IOP control with lower IOP values. Ocular surface status statistically improved when examined by TF-BUT and corneal staining.
authors.affiliation: University Eye Clinic of Pavia, IRCCS Policlinico San Matteo Foundation , Pavia , Italy +39 0382 503730 ; +39 0382 527006 ; gemma.rossi.md@gmail.com.
authors.forename: Gemma Caterina Maria
authors.initials: GC
authors.lastname: Rossi
authors.forename: Luigia
authors.initials: L
authors.lastname: Scudeller
authors.forename: Teresa
authors.initials: T
authors.lastname: Rolle
authors.forename: Gian Maria
authors.initials: GM
authors.lastname: Pasinetti
authors.forename: Paolo Emilio
authors.initials: PE
authors.lastname: Bianchi
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001548:Benzalkonium Compounds / Q000009:adverse effects / Q000737:chemistry; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy; D011108:Polymers / Q000009:adverse effects* / Q000737:chemistry; D011310:Preservatives, Pharmaceutical / Q000009:adverse effects* / Q000737:chemistry; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000009:adverse effects; D000069557:Travoprost / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000959:Antihypertensive Agents; D001548:Benzalkonium Compounds; D011108:Polymers; D011310:Preservatives, Pharmaceutical; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; C058655:polyquaternium 1; D000069557:Travoprost
keywords: Polyquad-preserved; Travoprost; efficacy; glaucoma; ocular surface disease; quality of life; tolerability